Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes serious adverse events (proportion) compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether methotrexate plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes adverse events compared with ursodeoxycholic acid (very low certainty).
1 finding from 1 review
Alkaline phosphatase · patients with primary biliary cirrhosis.
1 finding from 1 review
All‐cause mortality · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes all‐cause mortality compared with ursodeoxycholic acid (very low certainty).
1 finding from 1 review
Liver morbidity · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes liver morbidity compared with ursodeoxycholic acid (very low certainty).
1 finding from 1 review